#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immune thrombocytopenia Hereditary neuropathic amyloidosis Cardiac sarcoidosis Hidradenitis Antiphospholipid syndrome Pulmonary hypertension Immunodeficiency common variable Drug eruption Cold type haemolytic anaemia Ureteric cancer Complex regional pain syndrome Aicardi-Goutieres syndrome Neuroblastoma recurrent Glomerulonephritis Choroidal dystrophy More trials…

    Learn about Rare Diseases

    Hereditary ataxia Leiomyosarcoma – Basic Information Congenital generalised lipodystrophy – Life with Disease Pituitary-dependent Cushing’s syndrome – Trials in Disease Acquired haemophilia – Life with Disease Mastocytosis – Diagnostics Lymphatic malformation – Trials in Disease Rhabdomyosarcoma recurrent Amyotrophic lateral sclerosis – Basic Information Immunodeficiency congenital – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Benfotiamine Deucrictibant Thiotepa ALKYLATING AGENTS Mrna-4157 Xaluritamig Chlorpromazine ARFOLITIXORIN ADX-324 Gen3017 Ciclosporin A Tafamidis Cft1946 Levosimendan VERTEPORFIN Glucose, Anhydrous Stx-241 Zetomipzomib Rusfertide Cldn6 Car-T More therapies…

    Learn about Your Condition

    Neutropenia Staphylococcal infection Affective disorder Hypotransferrinaemia Appendicitis perforated Hypersensitivity Back pain Aortic stenosis Epicondylitis Anal cancer Hypotension Fatty acid oxidation disorder Peritoneal abscess Hyperlipidaemia Parkinson's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer metastatic

  • Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Cd152
    • Docetaxel
    Belgium Germany Italy The Netherlands Spain

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Divarasib
    • Budesonide
    • Carboplatin
    Belgium Denmark France Germany Greece Hungary +6

  • Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    France Germany Italy Spain

  • Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Docetaxel
    France Spain

  • Anti‑PD1 Therapy with pembrolizumab and cemiplimab in first‑line advanced non‑small cell lung cancer patients with high PD‑L1 expression

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Cemiplimab
    • Pembrolizumab
    France

  • A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ramucirumab
    • Rilvegostomig
    Belgium France Germany Italy The Netherlands Poland +1
Previous Page
1 … 3 4 5 6 7 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!